Skip to main content

Table 1 Demographics and Clinical Characteristics

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

  Galcanezumab 120 mg
N = 135
Galcanezumab 240 mg
N = 135
Age in years, mean (SD) 40.2 (11.7) 43.7 (11.0)*
Female, n (%) 110 (81.5) 113 (83.7)
Body mass index, kg/m2, mean (SD) 26.6 (5.4) 27.2 (5.8)
Race, n (%)
 Asian 2 (1.5) 0
 Black 6 (4.4) 8 (5.9)
 Multiple 23 (17.0) 19 (14.1)
 White 103 (76.3) 108 (80.0)
Episodic migraine, n (%) 109 (80.7) 104 (77.0)
Cardiovascular Disease Risk Group, n (%)a 22 (17.1) 28 (19.9)
Comorbid conditions, mean (SD)b 4.3 (3.2) 4.7 (3.4)
 Depression 19 (14.1) 26 (19.3)
 Seasonal Allergy 24 (17.8) 21 (15.6)
 Drug hypersensitivity 21 (15.6) 21 (15.6)
 Back pain 18 (13.3) 21 (15.6)
 Insomnia 19 (14.1) 20 (14.8)
 Anxiety 15 (11.1) 16 (11.9)
 Gastroesophageal reflux disease 12 (8.9) 16 (11.9)
Years since diagnosis, mean (SD) 20.2 (12.4) 21.3 (12.5)
Number of migraine headache days, mean (SD) 9.7 (5.8) 11.4 (6.7)*
Number of headache days, mean (SD) 5.0 (6.8) 6.1 (8.1)
Number of days with acute migraine medication use, mean (SD) 9.8 (6.6) 10.9 (7.2)
Prior preventive treatment, n (%) 81 (60.0) 88 (65.2)
Patient Global Impression - Severity, mean (SD) 4.7 (1.2) 4.7 (1.2)
Migraine Disability Assessment total, mean (SD) 45.8 (42.1) 54.0 (61.2)
Migraine-Specific Questionnaire Role Function-Restrictive domain score, mean (SD) 47.4 (19.2) 47.7 (18.4)
  1. SD standard deviation
  2. aPatients with a history or pre-existing condition listed in any of the following MedDRA Standardized Queries: Ischaemic Heart Disease, Hypertension, Cardiac Failure, Cardiomyopathy, Ischaemic CNS Vascular Conditions, Dyslipidaemia, Hyperglycaemia/New Onset Diabetes Mellitus
  3. bMost common comorbid conditions (≥10%) are reported. *P < .05